# US Immunoassay Market

> US Immunoassay Market Research Report By Type (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Fluorescent Immunoassay, Chemiluminescent Immunoassay, Western Blot), By Technology (Automated Immunoassay, Point of Care Immunoassay, Lateral Flow Assay), By Application (Clinical Diagnostics, Drug Development, Environmental Testing, Food Safety Testing) and By End Use (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Academic Research Institutions) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.18%
- **2024:** $ 6.5 Billion
- **2025:** $ 6.77 Billion
- **2035:** $ 10.2 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), PerkinElmer (US)

**Report ID:** MRFR/MED/48765-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-immunoassay-market-50522

---

## Market Summary

## **US Immunoassay Market Overview**

As per MRFR analysis, the US Immunoassay Market Size was estimated at 3.89 (USD Billion) in 2023. The US Immunoassay Market Industry is expected to grow from 4.04 (USD Billion) in 2024 to 6.37 (USD Billion) by 2035. The US Immunoassay Market CAGR (growth rate) is expected to be around 4.223% during the forecast period (2025 - 2035).

### **Key US Immunoassay Market Trends Highlighted**

The US Immunoassay Market is experiencing several significant trends driven largely by ongoing innovations in technology and increasing demand for accurate diagnostics. One of the key market drivers is the rising prevalence of chronic diseases, which necessitates the need for early diagnosis and monitoring. As the population ages, there is a greater focus on preventive healthcare, which further supports the usage of immunoassay testing in clinical laboratories and hospitals. The increasing awareness about health and wellness is pushing healthcare providers and patients towards advanced diagnostic methods, thereby driving market growth.

Recent advances in point-of-care testing and the development of high-throughput assays are transforming how immunoassays are performed, making them more efficient and accessible.

Furthermore, the possibility for the integration of new technology in healthcare facilities is being facilitated by rapid diagnostics regulatory advocates for healthcare innovation. There is also a gap to be filled in personalized medicine where immunodiagnostics could be essential in individualizing treatment regimens for patients. In addition, there is a growing demand for testing done in the comfort of home in the United States.

The focus on home testing, which public health paradigms greatly pushed during the pandemic, is still stimulating the development of easy-to-use and accurate immunoassay test kits by manufacturers, who traditionally did not market products for consumer use. As the US healthcare system stakeholders undergo these transitions, leveraging these opportunities will improve patient care and grow the market in the immunoassay diagnostic field.

Consequently, the US Immunoassay Market is set to evolve with these emerging trends impacting the future direction of diagnostics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **US Immunoassay Market Drivers**

### **Increasing Prevalence of Chronic Diseases**

The rise in the prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is significantly driving the US Immunoassay Market Industry. Data from the Centers for Disease Control and Prevention (CDC) indicates that approximately 6 in 10 adults in the United States live with at least one chronic disease, with diabetes alone affecting over 34 million people. This increasing patient population leads to a higher demand for early diagnostic and monitoring solutions, where immunoassays play a vital role.

Established organizations such as the American Diabetes Association and the American Heart Association continuously advocate for improved screening and diagnostic tests, which favorably positions the immunoassay market for growth. As new and advanced immunoassay technologies emerge, the increasing volume of chronic disease diagnoses is expected to further enhance market dynamics, thus contributing to the projected growth in the period up to 2035.

### **Technological Advancements in Immunoassay Techniques**

Advancements in immunoassay technology, including the development of point-of-care testing and high-throughput screening, are driving the US Immunoassay Market Industry robustly. New platforms enable rapid testing and increase the efficiency of testing and diagnosis. The Food and Drug Administration (FDA) has approved several innovative immunoassay devices that enhance sensitivity and specificity, which is expected to broaden diagnostic capabilities in various healthcare settings.

Notably, companies like Abbott Laboratories and Siemens Healthineers are continuously innovating, creating high-quality testing devices that meet the evolving healthcare demands. Increased investments in Research and Development by these organizations enhance the potential for novel immunoassay solutions, further solidifying their essential role in diagnostics, particularly amid an evolving healthcare landscape in the United States.

### **Growing Demand for Precision Medicine**

The growing focus on precision medicine is significantly influencing the US Immunoassay Market Industry. As healthcare moves toward personalized treatment protocols, immunoassays are becoming crucial for tailoring therapies to individual patient profiles. A report from the National Cancer Institute indicates that precision medicine strategies can lead to better treatment efficacy, with immunoassays providing critical biomarker information for targeted therapies.

Major healthcare institutions like Mayo Clinic and Cleveland Clinic have already adopted such approaches, leading to improved patient outcomes. Such transformations in treatment paradigms not only accentuate the need for immunoassays but also indicate that this market could see substantial growth in response to increasing regulatory and clinical emphasis on personalized care.

## **US Immunoassay Market Segment Insights**

### **Immunoassay Market Type Insights**

The Type segment of the US Immunoassay Market represents a significant portion of the overall landscape, reflecting the diversity and specialization of diagnostic techniques utilized in various applications, particularly within clinical laboratories and research environments. The Enzyme-Linked Immunosorbent Assay (ELISA) is widely recognized for its ability to provide high-throughput screening capabilities, making it essential in both clinical diagnostics and Research and Development endeavors. Similarly, Radioimmunoassay (RIA) remains a cornerstone for hormone and drug level measurements, particularly in specialized settings where sample sensitivity is paramount, thus contributing noticeably to market dynamics.

Fluorescent Immunoassay (FIA) boasts enhanced sensitivity and specificity, catering to the need for rapid diagnostics in infectious disease detection, an area that has seen increased demand in recent years due to emerging pathogens. Chemiluminescent Immunoassay (CLIA) has gained traction for its efficiency and robustness in quantitative analysis, making it the preferred choice for many assays, particularly in hospital laboratories focused on patient management and monitoring. Western Blotting is a critical technique in confirmatory testing for various diseases, including HIV, reinforcing its importance in the overall diagnostic hierarchy.

The interplay between these types highlights not only the technological advancements but also the ongoing need for accuracy and reliability in immunodiagnostics. With a growing emphasis on precision medicine and personalized healthcare, the US Immunoassay Market is poised to adapt and evolve, leveraging these distinct immunoassay methods to meet the demands of an ever-changing landscape in diagnostics and therapeutic monitoring across various medical disciplines. As the population ages and the prevalence of chronic diseases rises, the US Immunoassay Market stands to benefit significantly from the increasing need for comprehensive diagnostic solutions that these immunoassay types provide.

Continuous investments in technological innovation and the expansion of applications in clinical settings underscore the importance of this Type segmentation within the broader market, enabling healthcare professionals to deliver targeted and effective treatments to patients. These dynamics not only shape competitive strategies but also influence the regulatory landscape, as advancements must often align with the rigorous standards established by health authorities to ensure patient safety and treatment efficacy.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Immunoassay Market Technology Insights**

The US Immunoassay Market, particularly within the Technology segment, showcases significant growth driven by advancements in diagnostic capabilities. Key methodologies include Automated Immunoassay, Point of Care Immunoassay, and Lateral Flow Assay, each playing a crucial role in enhancing testing efficiency and accuracy. Automated Immunoassays are pivotal in laboratory settings, offering high-throughput testing that is essential for clinical diagnostics and disease monitoring. In contrast, Point of Care Immunoassays deliver rapid results, facilitating immediate clinical decisions and improving patient outcomes in various healthcare settings.

Meanwhile, Lateral Flow Assays remain highly popular due to their simplicity and cost-effectiveness, making them ideal for home testing and emergency diagnostics. As the healthcare landscape in the US continues to evolve, these technologies cater to the growing demand for reliable and timely diagnostic solutions, making the US Immunoassay Market a vital part of the healthcare industry with ongoing innovations and applications in disease management. The expansion of these methodologies indicates a strong potential for market growth as they adapt to the diverse needs of healthcare providers and patients across the country.

### **Immunoassay Market Application Insights**

The US Immunoassay Market, particularly within the Application segment, is characterized by its critical roles in various fields, including Clinical Diagnostics, Drug Development, Environmental Testing, and Food Safety Testing. Clinical Diagnostics remains a vital area, as the demand for accurate and rapid diagnostic tools continues to rise, driven by the increasing prevalence of chronic diseases and the emphasis on preventive healthcare. In Drug Development, immunoassays facilitate the evaluation of drug efficacy and safety, which is essential for regulatory approvals.

Environmental Testing is gaining traction due to the need for stringent monitoring of pollutants and pathogens, aligning with US regulatory standards for public health. Food Safety Testing also plays a significant role in ensuring that food products meet safety regulations and consumer expectations by testing for contaminants, allergens, and pathogens. This diverse range of applications highlights the importance of the US Immunoassay Market and its potential for growth in addressing critical health and safety challenges faced by society today. The adaptability of immunoassay technologies fosters numerous opportunities, bolstering its pivotal position across these essential sectors.

### **Immunoassay Market End Use Insights**

The US Immunoassay Market showcases a diverse array of end uses, primarily comprising hospitals, diagnostic laboratories, pharmaceutical companies, and academic research institutions. Hospitals are vital in administering immunoassays for diagnosing diseases and monitoring patient health, emphasizing the growing recognition of early detection in patient care. Diagnostic laboratories, on the other hand, play a pivotal role as they heavily rely on immunoassay techniques to deliver accurate and timely test results, thus supporting effective clinical decision-making.

Pharmaceutical companies utilize immunoassays extensively in drug discovery and development stages, thereby enhancing their Research and Development initiatives by allowing for precise biomarker measurements. In contrast, academic research institutions leverage immunoassay technologies to advance scientific knowledge, focusing on diverse fields such as immunology, oncology, and infectious diseases. This segmentation highlights the multifaceted applications of immunoassays across various sectors, driving significant market growth and emphasizing the essential role these technologies play in enhancing healthcare outcomes within the United States.

As the adoption of innovative technologies continues to rise, the importance of these segments remains paramount in shaping the landscape of the US Immunoassay Market.

## **US Immunoassay Market Key Players and Competitive Insights**

The US Immunoassay Market is highly competitive and exhibits significant growth driven by technological advancements, increased demand for diagnostic testing, and expanding applications in various fields, including clinical diagnostics, infectious disease testing, and oncology. As the market evolves, key players are focusing on innovation in product development, enhancing operational capabilities, and forming strategic partnerships to secure their market positions. Companies are also paying close attention to regulatory compliance and expanding their portfolios to cater to the rising needs of healthcare providers and diagnostic laboratories in the United States.

This competitive landscape highlights the importance of agility and adaptability as firms navigate market dynamics while striving to meet patient and clinician needs efficiently.

### **Quidel Corporation**

Quidel Corporation has established a commanding presence in the US Immunoassay Market, recognized for its extensive range of diagnostic testing solutions. The company excels in developing rapid immunoassays, especially for infectious diseases, which has positioned it as a leader in point-of-care testing. Quidel's strengths include its commitment to innovation, as evidenced by its continuous investment in research and development aimed at introducing novel diagnostic technologies. Moreover, its established distribution network and collaboration with healthcare providers enhance its reach and ability to swiftly deliver results to the market.

The company's reputation for reliability and accuracy in its test offerings further solidifies its competitive edge within the US immunoassay sector.

### **Sysmex Corporation**

Sysmex Corporation is another notable player in the US Immunoassay Market, distinguished by its advanced laboratory technology and integrated diagnostic solutions. The company specializes in hematology and immunochemistry, offering a variety of immunoassay analyzers and reagents that cater to both clinical laboratories and hospitals. Sysmex is recognized for its innovative technologies aimed at enhancing laboratory efficiency and accuracy in diagnostic testing. The company's strengths lie in its robust research and development capabilities, allowing it to continually introduce cutting-edge products that meet the evolving demands of the healthcare landscape.

Additionally, through strategic mergers and acquisitions, Sysmex has expanded its product offerings and enhanced its market presence in the US, allowing for a broader and more integrated approach to immunoassay testing that positions it well for ongoing growth and customer satisfaction in this competitive market.

### **Key Companies in the US Immunoassay Market Include**

## **US Immunoassay Market Industry Developments**

The US Immunoassay Market has seen notable developments in recent months. In October 2023, Quidel Corporation announced the launch of a new point-of-care immunoassay that enhances rapid diagnostics for respiratory illnesses, responding to increased demand for efficient testing solutions. In September 2023, Abbott Laboratories showcased its advancements in COVID-19 immunoassay technology, emphasizing faster result times, which is crucial in managing public health concerns.

Additionally, in August 2023, Thermo Fisher Scientific debuted a streamlined immunoassay platform aimed at improving laboratory workflows and increasing throughput. Mergers and acquisitions have also shaped the market; for instance, in July 2023, Merck KGaA completed its acquisition of a small biotech firm focused on immunoassay technology, positioning itself strategically for future growth.

Companies like Siemens Healthineers and Roche Diagnostics continue to invest heavily in Research and Development, further advancing innovations within the market. The increasing prevalence of chronic diseases in the US, alongside advancements in technology, is significantly driving the immunoassay market's growth, further solidifying the competitive landscape among key players such as Hologic, BioRad Laboratories, and Danaher Corporation.

## **US Immunoassay Market Segmentation Insights**

### **Immunoassay Market Type Outlook**

### **Immunoassay Market Technology Outlook**

### **Immunoassay Market Application Outlook**

### **Immunoassay Market End Use Outlook**

## Market Drivers

### Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune conditions is a primary driver for the immunoassay market. As these diseases require regular monitoring and management, the demand for diagnostic tools that can provide accurate and timely results is surging. According to recent data, chronic diseases account for approximately 70% of all deaths in the US, highlighting the urgent need for effective diagnostic solutions. This trend is likely to propel the growth of the immunoassay market, as healthcare providers seek reliable methods to diagnose and monitor these conditions. Furthermore, advancements in immunoassay technologies are expected to enhance the accuracy and efficiency of disease detection, further driving market expansion.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is significantly influencing the immunoassay market. As healthcare providers increasingly focus on tailored treatment plans based on individual patient profiles, the need for precise diagnostic tools becomes paramount. Immunoassays play a crucial role in identifying biomarkers that guide treatment decisions, thereby enhancing patient outcomes. The market for personalized medicine is expected to grow at a CAGR of over 10% in the coming years, indicating a robust demand for immunoassay technologies. This trend suggests that the immunoassay market will likely expand as more healthcare professionals adopt these tests to provide customized care, aligning with the broader movement towards personalized healthcare.

### Rising Awareness of Preventive Healthcare

There is a growing awareness of preventive healthcare among the US population, which is likely to impact the immunoassay market positively. As individuals become more proactive about their health, the demand for diagnostic tests that facilitate early disease detection is increasing. Public health campaigns and educational initiatives are contributing to this trend, encouraging people to undergo regular health screenings. This shift towards preventive measures is expected to drive the utilization of immunoassays, as they provide critical information for early diagnosis and intervention. Consequently, the immunoassay market may experience substantial growth as more individuals seek out these tests as part of their routine healthcare.

### Technological Innovations in Assay Development

Technological innovations in assay development are driving the evolution of the immunoassay market. The introduction of novel techniques such as multiplex assays, which allow simultaneous detection of multiple analytes, is enhancing the efficiency and effectiveness of diagnostic testing. These advancements are not only improving the speed of results but also increasing the accuracy of disease detection. The market for multiplex immunoassays is projected to grow significantly, reflecting the demand for more comprehensive testing solutions. Furthermore, the integration of automation and artificial intelligence in assay development is expected to streamline processes, reduce human error, and ultimately drive the growth of the immunoassay market.

### Increased Investment in Healthcare Infrastructure

The US government and private sector are significantly investing in healthcare infrastructure, which is likely to bolster the immunoassay market. Enhanced funding for hospitals, laboratories, and research institutions is facilitating the adoption of advanced diagnostic technologies. For instance, the US healthcare expenditure is projected to reach $4.3 trillion by 2025, with a substantial portion allocated to diagnostic services. This investment is expected to improve access to immunoassay testing, thereby increasing its utilization in clinical settings. Additionally, the establishment of new laboratories and diagnostic centers is anticipated to create a favorable environment for the growth of the immunoassay market, as more facilities will be equipped to perform these tests.

## Future Outlook

The [Immunoassay Market](https://www.marketresearchfuture.com/reports/immunoassay-market-5841) is projected to grow at 4.18% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and rising healthcare expenditure.

**New opportunities:**

- Development of point-of-care testing devices for rapid diagnostics. Integration of AI in immunoassay platforms for enhanced accuracy. Expansion of immunoassay applications in personalized medicine and therapeutics.

By 2035, the immunoassay market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Chemiluminescent Immunoassay (Largest) vs. Fluorescent Immunoassay (Fastest-Growing)

In the US immunoassay market, Chemiluminescent Immunoassay holds the largest market share due to its high sensitivity and rapid results. Enzyme-Linked Immunosorbent Assay is another significant player, while Western Blot and Radioimmunoassay comprise a smaller portion of the market. Overall, the distribution varies, with Chemiluminescent technologies leading in diagnostics.

Looking forward, Fluorescent Immunoassay is emerging as the fastest-growing segment, driven by advancements in imaging technologies and the increasing demand for point-of-care testing. The trend toward automation and the development of more sensitive reagents further boost growth. As healthcare facilities seek quicker diagnoses, Fluorescent Immunoassays are set to capture a larger share of the market, redefining diagnostics in the sector.

Chemiluminescent Immunoassay (Dominant) vs. Fluorescent Immunoassay (Emerging)

Chemiluminescent Immunoassay is highly regarded for its superior sensitivity and efficiency in detecting biomarkers, making it the dominant technology in the US immunoassay market. Its ability to deliver results with minimal sample volume while maintaining accuracy positions it as a preferred choice for various diagnostic applications. In contrast, Fluorescent Immunoassay is gaining traction as an emerging technology, appealing to laboratories and clinics for its rapid results and ease of use. The simplicity of workflow and capacity for multiplexing in Fluorescent Immunoassay supports its adoption and reflects a trend towards innovative diagnostic solutions that enhance patient care.

### By Technology: Automated Immunoassay (Largest) vs. Point of Care Immunoassay (Fastest-Growing)

In the US immunoassay market, the distribution of market share among the technology segment values reveals a very competitive landscape. Automated Immunoassay continues to hold the largest share thanks to its efficiency and accuracy, making it the preferred choice in laboratory settings. Point of Care Immunoassay, while smaller in current share, is rapidly gaining traction due to its convenience and the growing demand for immediate diagnostic results, especially in emergency medical settings.

Growth trends indicate a shift towards more accessible and automated diagnostic solutions, with the introduction of innovative technologies enhancing the capabilities of Point of Care Immunoassay. The increasing geriatric population and rising prevalence of chronic diseases are significant drivers fueling the demand for both Automated and Point of Care Immunoassay technologies. Additionally, the ongoing advancements in assay methods and favorable healthcare policies facilitate market expansion and propel the adoption of advanced immunoassays.

Technology: Automated Immunoassay (Dominant) vs. Point of Care Immunoassay (Emerging)

Automated Immunoassay, being the dominant segment, is characterized by its high throughput and minimal human intervention, which enhances workflow efficiency in laboratories. This technology employs sophisticated equipment to perform multiple tests quickly and reliably, catering to the needs of large testing facilities. On the other hand, Point of Care Immunoassay is an emerging segment that emphasizes rapid testing capabilities and user-friendly designs, allowing healthcare providers to deliver quick results directly at the patient's location. The growth of this segment is driven by a heightened focus on patient-centric care and the move towards decentralized testing, making it a key player in the future landscape of the US immunoassay market.

### By Application: Clinical Diagnostics (Largest) vs. Drug Development (Fastest-Growing)

In the US immunoassay market, Clinical Diagnostics represents the largest segment by a significant margin, driven by the increasing demand for accurate and efficient disease diagnosis. This segment encompasses a wide range of applications, including routine testing and complex disease detection, capturing a substantial market share. In contrast, Drug Development has emerged as the fastest-growing segment due to the rising need for innovative drugs and therapies, contributing to advancements in pharmacogenomics and personalized medicine.

The growth trends in the US immunoassay market are largely attributed to technological advancements, regulatory support, and growing healthcare expenditure. Increased awareness of health and fitness, along with a surge in chronic diseases, has propelled Clinical Diagnostics. Meanwhile, the expansion in Drug Development is driven by a focus on precision medicine, necessitating sophisticated testing methods, and a surge in collaborations between biotechnology firms and research institutions dedicated to drug discovery and validation.

Clinical Diagnostics: Dominant vs. Drug Development: Emerging

Clinical Diagnostics is characterized by its robust infrastructure and established protocols that ensure high reliability and accuracy in testing. This segment has a well-defined market presence owing to existing regulatory frameworks and a plethora of testing options available, catering to various healthcare needs. On the other hand, Drug Development represents an emerging but dynamic sector within the US immunoassay market. It is characterized by rapid innovation and high adaptability to technological advancements. Companies in this space are focused on developing tests that support drug efficacy and safety assessment, driving significant funding and research efforts that emphasize personalized medical solutions.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US immunoassay market, the distribution of market share among end-use segments is notably varied. Hospitals hold the largest market share as they are primary users of immunoassay technologies, leveraging these tests for patient diagnosis and management. Diagnostic laboratories also play a crucial role, providing specialized testing services that cater to a wide range of medical needs and disease detection, thereby maintaining a significant portion of the market share.

Growth trends within this segment are primarily driven by an increasing demand for rapid and accurate diagnostic testing across healthcare facilities. Hospitals continue to invest in advanced immunoassay technologies to enhance their testing capabilities. Meanwhile, diagnostic laboratories are experiencing rapid growth as they increasingly adopt automation and high-throughput testing solutions to meet rising patient demand, positioning them as the fastest-growing segment alongside hospitals.

Hospitals: Dominant vs. Diagnostic Laboratories: Emerging

Hospitals represent the dominant force in the end-use segment of the US immunoassay market, characterized by their comprehensive integration of immunoassay tests in routine patient care. With their extensive infrastructure and access to vast patient populations, hospitals utilize these assays for a range of diagnostic purposes, including infectious disease testing and chronic disease management. In contrast, diagnostic laboratories are emerging as a vital segment, driven by technological advancements and a specialization in niche testing services. They are increasingly adopting innovative immunoassay technologies to provide rapid and precise results. This shift enables them to compete effectively against larger healthcare facilities and cater to the growing demand for specialized tests, making them a significant player in the market.

## Competitive Benchmarking

The immunoassay market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations among key players. Major companies such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, leveraging their extensive research capabilities and technological advancements to enhance product offerings. Abbott Laboratories (US) focuses on expanding its diagnostic portfolio through strategic partnerships, while Roche Diagnostics (CH) emphasizes innovation in personalized healthcare solutions. Thermo Fisher Scientific (US) is actively pursuing digital transformation initiatives to streamline operations and improve customer engagement, collectively shaping a competitive environment that prioritizes technological advancement and customer-centric solutions. Key business tactics within the immunoassay market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Danaher Corporation (US) and Siemens Healthineers (DE) is notable, as they implement strategies that not only enhance their market presence but also drive overall market growth through competitive pricing and innovative product development. In October 2025, Danaher Corporation (US) announced the acquisition of a leading immunoassay technology firm, a move that is likely to bolster its capabilities in the diagnostics sector. This acquisition is strategically significant as it allows Danaher to integrate advanced technologies into its existing product lines, thereby enhancing its competitive edge and expanding its market reach. The integration of new technologies could potentially lead to improved diagnostic accuracy and faster turnaround times, aligning with current market demands for efficiency and reliability. In September 2025, Siemens Healthineers (DE) launched a new line of immunoassay analyzers designed to improve throughput and reduce operational costs for laboratories. This strategic initiative reflects Siemens' commitment to innovation and operational excellence, positioning the company to capture a larger share of the market. The introduction of these analyzers is expected to meet the growing demand for high-quality diagnostic solutions, thereby reinforcing Siemens' competitive position in the immunoassay landscape. In November 2025, Roche Diagnostics (CH) unveiled a partnership with a leading tech firm to develop AI-driven diagnostic tools. This collaboration is indicative of Roche's strategic focus on integrating artificial intelligence into its product offerings, which may enhance diagnostic accuracy and efficiency. The partnership not only underscores Roche's commitment to innovation but also highlights a broader trend within the industry towards the adoption of advanced technologies to improve patient outcomes and streamline laboratory processes. As of November 2025, current competitive trends in the immunoassay market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a crucial role in shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and enhanced customer engagement. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in an increasingly competitive environment.

## Recent News & Developments

The US Immunoassay Market has seen notable developments in recent months. In October 2023, Quidel Corporation announced the launch of a new point-of-care immunoassay that enhances rapid diagnostics for respiratory illnesses, responding to increased demand for efficient testing solutions. In September 2023, Abbott Laboratories showcased its advancements in COVID-19 immunoassay technology, emphasizing faster result times, which is crucial in managing public health concerns.

Additionally, in August 2023, Thermo Fisher Scientific debuted a streamlined immunoassay platform aimed at improving laboratory workflows and increasing throughput. Mergers and acquisitions have also shaped the market; for instance, in July 2023, Merck KGaA completed its acquisition of a small biotech firm focused on immunoassay technology, positioning itself strategically for future growth.

Companies like Siemens Healthineers and Roche Diagnostics continue to invest heavily in Research and Development, further advancing innovations within the market. The increasing prevalence of chronic diseases in the US, alongside advancements in technology, is significantly driving the immunoassay market's growth, further solidifying the competitive landscape among key players such as Hologic, BioRad Laboratories, and Danaher Corporation.

## Report Scope

| MARKET SIZE 2024 | 6.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.77(USD Billion) |
| MARKET SIZE 2035 | 10.2(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.18% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), PerkinElmer (US) |
| Segments Covered | Type, Technology, Application, End Use |
| Key Market Opportunities | Advancements in point-of-care testing technologies enhance accessibility in the immunoassay market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the immunoassay market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall valuation of the US immunoassay market in 2024?**
A: The overall market valuation was $6.5 Billion in 2024.

**Q: What is the projected market valuation for the US immunoassay market by 2035?**
A: The projected valuation for 2035 is $10.2 Billion.

**Q: What is the expected CAGR for the US immunoassay market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 4.18%.

**Q: Which companies are considered key players in the US immunoassay market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Ortho Clinical Diagnostics, and PerkinElmer.

**Q: What are the main types of immunoassays and their market valuations in 2024?**
A: In 2024, Enzyme-Linked Immunosorbent Assay was valued at $2.6 Billion, Radioimmunoassay at $1.0 Billion, Fluorescent Immunoassay at $1.2 Billion, Chemiluminescent Immunoassay at $1.5 Billion, and Western Blot at $0.2 Billion.

**Q: How does the market for automated immunoassays compare to point of care immunoassays in 2024?**
A: In 2024, the market for automated immunoassays was valued at $2.6 Billion, while point of care immunoassays were valued at $1.5 Billion.

**Q: What applications are driving growth in the US immunoassay market?**
A: Key applications include Clinical Diagnostics valued at $2.6 Billion, Drug Development at $1.5 Billion, Environmental Testing at $1.0 Billion, and Food Safety Testing at $1.4 Billion in 2024.

**Q: Which end-use segments are most prominent in the US immunoassay market?**
A: In 2024, hospitals led with a valuation of $2.6 Billion, followed by diagnostic laboratories at $1.8 Billion, pharmaceutical companies at $1.5 Billion, and academic research institutions at $0.6 Billion.

**Q: What is the anticipated growth trend for the US immunoassay market from 2025 to 2035?**
A: The market is expected to grow steadily, reaching $10.2 Billion by 2035, indicating a robust growth trajectory.

**Q: How do the valuations of different immunoassay types evolve from 2024 to 2035?**
A: Valuations for types like Enzyme-Linked Immunosorbent Assay and Chemiluminescent Immunoassay are projected to increase significantly, reflecting the overall market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-immunoassay-market-50522*